• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Certara Inc. (Amendment)

    2/14/22 12:46:54 PM ET
    $CERT
    Computer Software: Prepackaged Software
    Technology
    Get the next $CERT alert in real time by email
    SC 13G/A 1 tm226510d1_sc13ga.htm SC 13G/A

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

     

     

     

    Certara, Inc.

    (Name of Issuer)

     

    Common Stock, par value $0.01 per share

    (Titles of Class of Securities)

     

    15687V109

    (CUSIP Number)

     

    December 31, 2021

    (Date of Event Which Requires Filing of this Statement)

     

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨ Rule 13d-1(b)

     

    ¨ Rule 13d-1(c)

     

    x Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out of a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended (the “Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    Schedule 13G

     

    CUSIP No. 15687V109 Page 2 of 11

     

    1  

    NAME OF REPORTING PERSON

     

    EQT Avatar Parent L.P.

    2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨      (b) ¨

     

    3  

    SEC USE ONLY

     

    4  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

    5  

    SOLE VOTING POWER

     

    37,458,939

    6  

    SHARED VOTING POWER

     

    0

    7  

    SOLE DISPOSITIVE POWER

     

    37,458,939

    8  

    SHARED DISPOSITIVE POWER

     

    0

    9  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    37,458,939

    10  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES  ¨

     

    11  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    23.5%

    12  

    TYPE OF REPORTING PERSON

     

    PN

     

     

     

     

    Schedule 13G

     

    CUSIP No. 15687V109 Page 3 of 11

     

    1  

    NAME OF REPORTING PERSON

     

    EQT Avatar Parent GP LLC

    2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨      (b) ¨

     

    3  

    SEC USE ONLY

     

    4  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

    5  

    SOLE VOTING POWER

     

    37,458,939

    6  

    SHARED VOTING POWER

     

    0

    7  

    SOLE DISPOSITIVE POWER

     

    37,458,939

    8  

    SHARED DISPOSITIVE POWER

     

    0

    9  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    37,458,939

    10  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES  ☐

     

    11  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    23.5%

    12  

    TYPE OF REPORTING PERSON

     

    OO

     

     

     

     

    Schedule 13G

     

    CUSIP No. 15687V109 Page 4 of 11

     

    1  

    NAME OF REPORTING PERSON

     

    EQT Fund Management S.à r.l.

    2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨      (b) ¨

     

    3  

    SEC USE ONLY

     

    4  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Luxembourg

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

    5  

    SOLE VOTING POWER

     

    37,458,939

    6  

    SHARED VOTING POWER

     

    0

    7  

    SOLE DISPOSITIVE POWER

     

    37,458,939

    8  

    SHARED DISPOSITIVE POWER

     

    0

    9  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    37,458,939

    10  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES  ☐

     

    11  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    23.5%

    12  

    TYPE OF REPORTING PERSON

     

    OO

     

     

     

     

    Schedule 13G

     

    CUSIP No. 15687V109 Page 5 of 11

     

    Item 1(a). Name of Issuer:

     

    Certara, Inc.

     

    Item 1(b). Address of Issuer’s Principal Executive Offices:

     

    100 Overlook Center, Suite 101

    Princeton, New Jersey 08540

     

    Item 2(a). Name of Person Filing:

     

    This Amendment Number 1 to the Statement on Schedule 13G filed on February 16, 2021 (“Amendment No. 1”) is being filed jointly by EQT Avatar Parent L.P. (the “EQT Investor”), EQT Avatar Parent GP LLC (“Avatar Parent GP”), and EQT Fund Management S.à r.l. (“EFMS”) (each a “Reporting Person” and, together, the “Reporting Persons”), pursuant to an agreement of joint filing, a copy of which is attached hereto as Exhibit 1.

     

    Avatar Parent GP is the general partner of the EQT Investor. Several investment vehicles collectively make up the fund known as “EQT VII.” EQT VII owns 100% of the membership interests in Avatar Parent GP. EFMS has exclusive responsibility for the management and control of the business and affairs of investment vehicles which constitute the majority of the total commitments to EQT VII. As such, EFMS has the power to control Avatar Parent GP's voting and investment decisions and may be deemed to have beneficial ownership of the securities held by the EQT Investor. EFMS is managed by a five-member board of directors.

     

    Each of Avatar Parent GP and EFMS may be deemed to beneficially own the shares of Common Stock (as defined below) beneficially owned by the EQT Investor, but neither the filing of this Amendment No. 1 nor any of its contents shall be deemed to constitute an admission that any Reporting Person (other than the EQT Investor) is the beneficial owner of the Common Stock referred to herein for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended (the “Act”), or for any other purpose and each of Avatar Parent GP and EFMS expressly disclaim beneficial ownership of such shares. The filing of this statement should not be construed to be an admission that any of the Reporting Persons are members of a “group” for the purposes of Sections 13(d) and 13(g) of the Act.

     

    Item 2(b). Address of Principal Business Office or, if none, Residence:

     

    The address of the principal business office of the EQT Investor and Avatar Parent GP is:

     

    c/o EQT Partners

    1114 Avenue of the Americas, 45th Floor

    New York, NY 10036

     

    The address of the principal business office of EFMS is:

     

    26A, Boulevard Royal,

    L-2449 Luxembourg, Grand Duchy of Luxembourg

     

    Item 2(c). Citizenship:

     

    See response to Item 4 of each of the cover pages and Item 2(a) above.

     

    Item 2(d). Titles of Classes of Securities:

     

    Common stock, par value $0.01 per share (“Common Stock”).

      

    Item 2(e). CUSIP Number:

     

    15687V109

      

     

     

     

    Schedule 13G

     

    CUSIP No. 15687V109 Page 6 of 11

     

    Item 3. If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a(n):

     

    Not applicable.

     

    Item 4. Ownership

     

      (a) Amount Beneficially Owned:

     

    The information contained in rows 5, 6, 7, 8, 9, 10, and 11 on each of the cover pages of this Amendment No. 1 and the information set forth or incorporated in Item 2(a) is incorporated by reference in its entirety into this Item 4.

     

    The Reporting Persons may be deemed to beneficially own an aggregate of 37,458,939 shares of the Issuer’s Common Stock, which constitutes approximately 23.5% of the total outstanding Common Stock of the Issuer, based upon an aggregate of 159,658,948 shares of Common Stock outstanding as of December 31, 2021.

     

      (b) Percent of Class:

     

    See responses to Item 11 on each cover page and Items 2(a) and 4(a) above.

     

      (c) Number of shares as to which such person has:

     

      (i) Sole power to vote or to direct the vote:

     

    See responses to Item 5 on each cover page and Items 2(a) and 4(a) above.

     

      (ii) Shared power to vote or to direct the vote:

     

    See responses to Item 6 on each cover page and Items 2(a) and 4(a) above.

     

      (iii) Sole power to dispose or to direct the disposition of:

     

    See responses to Item 7 on each cover page and Items 2(a) and 4(a) above.

     

      (iv) Shared power to dispose or to direct the disposition of:

     

    See responses to Item 8 on each cover page and Items 2(a) and 4(a) above.

     

    Item 5. Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ¨.

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

     

    The several investment vehicles that collectively constitute the EQT VII fund may be deemed to have the indirect right to receive or the indirect power to direct the receipt of dividends from, or the proceeds from the sale of, the Common Stock held by the EQT Investor by virtue of their ownership of Avatar Parent GP’s membership interests. Of these vehicles, each of EQT VII (No. 1) Limited Partnership and EQT VII (No. 2) Limited Partnership may be deemed to have the indirect right to receive or the indirect power to direct the receipt of dividends from, or the proceeds from the sale of, 5.0% or more of the Issuer’s outstanding Common Stock.

     

     

     

     

    Schedule 13G

     

    CUSIP No. 15687V109 Page 7 of 11

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

     

    Not applicable.

     

    Item 8. Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Item 9. Notice of Dissolution of Group.

     

    Not applicable.

     

    Item 10. Certification.

     

    Not applicable.

     

     

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: February 14, 2022

     

      EQT Avatar Parent L.P.
      By: EQT Avatar Parent GP LLC, its general partner
       
      By: /s/ Marie Louise van Dam
        Name: Marie Louise van Dam
        Title:   President
         
      By: /s/ Adam Larsson
        Name: Adam Larsson
        Title:   Vice President
       
      EQT Avatar Parent GP LLC
       
      By: /s/ Marie Louise van Dam
        Name: Marie Louise van Dam
        Title:   President
         
      By: /s/ Adam Larsson
        Name: Adam Larsson
        Title:   Vice President
       
      EQT Fund Management S.à r.l.
       
      By: /s/ Peter Veldman
        Name: Peter Veldman
        Title:   Manager
       
      By:  /s/ Nicholas Curwen
        Name: Nicholas Curwen
        Title:   Manager

     

     

     

     

    Exhibit Index

     

    Exhibit 1   Agreement of Joint Filing as required by Rule 13d-1(k)(1) under the Act (incorporated by reference to Exhibit 1 to the Schedule 13G filed by the Reporting Persons on February 16, 2021).

     

     

    Get the next $CERT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CERT

    DatePrice TargetRatingAnalyst
    5/8/2025$14.00Equal Weight → Overweight
    Barclays
    2/27/2025$16.00Buy
    TD Cowen
    9/27/2024$16.00Neutral → Buy
    UBS
    4/10/2024$23.00Sector Weight → Overweight
    KeyBanc Capital Markets
    4/4/2024Mkt Perform
    JMP Securities
    2/26/2024$19.00Market Perform
    Leerink Partners
    12/7/2023$17.00Neutral
    UBS
    12/5/2023Sector Weight
    KeyBanc Capital Markets
    More analyst ratings

    $CERT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Certara Reports First Quarter 2025 Financial Results

      RADNOR, Pa., May 05, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today reported its financial results for the first quarter of fiscal year 2025. First Quarter Highlights: Revenue was $106.0 million, compared to $96.7 million in the first quarter of 2024, representing growth of 10%. Software revenue was $46.4 million, compared to $39.3 million in the first quarter of 2024, representing growth of 18%.Services revenue was $59.6 million, flat compared to $57.3 million in the first quarter of 2024, representing growth of 4%. Net income was $4.7 million, a $9.4 million increase compared to a net loss of $4.7 million in t

      5/5/25 4:15:00 PM ET
      $CERT
      Computer Software: Prepackaged Software
      Technology
    • Certara to Participate in Upcoming Investor Conferences

      RADNOR, Pa., April 29, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today announced that Company management will participate in the following investor conferences: BofA Securities 2025 Healthcare ConferenceDate and Time: Tuesday, May 13 at 3:40 p.m. PT William Blair 45th Annual Growth Stock ConferenceDate and Time: Wednesday, June 4 at 12:40 p.m. CT Live webcasts for each of the conferences will be available on Certara's investor relations website at https://ir.certara.com and will be available for replay for at least 90 days thereafter. About CertaraCertara accelerates medicines using biosimulation software, technology, and

      4/29/25 4:15:00 PM ET
      $CERT
      Computer Software: Prepackaged Software
      Technology
    • Certara Launches Non-Animal Navigator™ Solution to Help Drug Developers Reduce Reliance on Animal Testing

      RADNOR, Pa., April 14, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today announced the launch of its Non-Animal Navigator™ solution designed to help biopharmaceutical companies lead the transition ignited by the FDA's Roadmap to Reducing Animal Testing in Preclinical Safety Studies. The Roadmap marks a pivotal moment in drug development. Companies that act now can future-proof their portfolios, gaining competitive advantage through faster timelines, lower costs, and stronger predictive evidence. Globally, there are thousands of monoclonal antibodies and antibody-drug conjugates (ADCs) currently in the preclinical phase of devel

      4/14/25 8:15:00 AM ET
      $CERT
      Computer Software: Prepackaged Software
      Technology

    $CERT
    Leadership Updates

    Live Leadership Updates

    See more
    • Certara Appoints Dr. Adrian McKemey as President of Drug Development Solutions

      RADNOR, Pa., March 05, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today announced the appointment of Adrian McKemey, Ph.D. as President of Drug Development Solutions, effective March 3rd, 2025. In this role, McKemey will lead Certara's global team of drug development scientists. Adrian joins Certara after serving as head of Enterprise Transformation at IQVIA and Senior Vice President and Head of the R&D Strategy Solutions at Quintiles. He has over 25 years of experience in research and development roles where he focused on business transformation, portfolio management and R&D strategies. Before IQVIA, he was a Principal with t

      3/5/25 4:15:00 PM ET
      $CERT
      Computer Software: Prepackaged Software
      Technology
    • Certara Appoints John Reynders as New Independent Board Member

      RADNOR, Pa., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today announced the appointment of John Reynders, PhD, to its Board of Directors, effective October 15, 2024. "We are excited to welcome an accomplished pharmaceutical industry leader with a track record of success to Certara's Board," said William F. Feehery, PhD, CEO of Certara. "John's expertise in artificial intelligence, data science, and life science will provide immense value. We will draw on that expertise as we continue to develop and integrate transformational software and services that accelerate new medicines and increase the productivity of pharma R&

      10/16/24 4:15:00 PM ET
      $CERT
      Computer Software: Prepackaged Software
      Technology
    • MaxCyte Appoints Cynthia Collins to its Board of Directors

      ROCKVILLE, Md., Oct. 15, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ:MXCT, LSE: MXCT))), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and innovative bioprocessing applications, today announced the appointment of Cynthia Collins to the Company's Board of Directors as a non-executive director, effective October 14, 2024. Collins will serve on the board's compensation committee. Following her appointment, MaxCyte's total Board of Directors will increase to 10 members. "I am pleased to welcome Cynthia to MaxCyte's Board of Directors," said Mahe

      10/15/24 8:05:00 AM ET
      $CERT
      $MXCT
      $PSTX
      Computer Software: Prepackaged Software
      Technology
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $CERT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • PRESIDENT, PREDICTIVE TECH Aspbury Robert was granted 7,082 shares, covered exercise/tax liability with 15,846 shares and converted options into 26,626 shares, increasing direct ownership by 6% to 307,176 units (SEC Form 4)

      4 - Certara, Inc. (0001827090) (Issuer)

      4/3/25 4:44:38 PM ET
      $CERT
      Computer Software: Prepackaged Software
      Technology
    • PRESIDENT, CHIEF COMMERCAL OFF Pedersen Leif E was granted 7,082 shares, covered exercise/tax liability with 8,209 shares and converted options into 26,626 shares, increasing direct ownership by 26% to 125,203 units (SEC Form 4)

      4 - Certara, Inc. (0001827090) (Issuer)

      4/3/25 4:40:25 PM ET
      $CERT
      Computer Software: Prepackaged Software
      Technology
    • PRESIDENT, CHIEF COMMERCAL OFF Gallagher John E converted options into 42,486 shares and covered exercise/tax liability with 14,176 shares, increasing direct ownership by 155% to 46,528 units (SEC Form 4)

      4 - Certara, Inc. (0001827090) (Issuer)

      4/3/25 4:36:31 PM ET
      $CERT
      Computer Software: Prepackaged Software
      Technology

    $CERT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Certara upgraded by Barclays with a new price target

      Barclays upgraded Certara from Equal Weight to Overweight and set a new price target of $14.00

      5/8/25 8:23:49 AM ET
      $CERT
      Computer Software: Prepackaged Software
      Technology
    • TD Cowen initiated coverage on Certara with a new price target

      TD Cowen initiated coverage of Certara with a rating of Buy and set a new price target of $16.00

      2/27/25 6:17:48 AM ET
      $CERT
      Computer Software: Prepackaged Software
      Technology
    • Certara upgraded by UBS with a new price target

      UBS upgraded Certara from Neutral to Buy and set a new price target of $16.00

      9/27/24 7:31:50 AM ET
      $CERT
      Computer Software: Prepackaged Software
      Technology

    $CERT
    SEC Filings

    See more
    • SEC Form 10-Q filed by Certara Inc.

      10-Q - Certara, Inc. (0001827090) (Filer)

      5/5/25 4:31:57 PM ET
      $CERT
      Computer Software: Prepackaged Software
      Technology
    • Certara Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Certara, Inc. (0001827090) (Filer)

      5/5/25 4:24:47 PM ET
      $CERT
      Computer Software: Prepackaged Software
      Technology
    • Amendment: SEC Form SCHEDULE 13D/A filed by Certara Inc.

      SCHEDULE 13D/A - Certara, Inc. (0001827090) (Subject)

      4/14/25 5:15:03 PM ET
      $CERT
      Computer Software: Prepackaged Software
      Technology

    $CERT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Certara Inc.

      SC 13G - Certara, Inc. (0001827090) (Subject)

      11/14/24 8:38:56 AM ET
      $CERT
      Computer Software: Prepackaged Software
      Technology
    • Amendment: SEC Form SC 13G/A filed by Certara Inc.

      SC 13G/A - Certara, Inc. (0001827090) (Subject)

      10/4/24 10:25:50 AM ET
      $CERT
      Computer Software: Prepackaged Software
      Technology
    • SEC Form SC 13G/A filed by Certara Inc. (Amendment)

      SC 13G/A - Certara, Inc. (0001827090) (Subject)

      2/13/24 5:01:03 PM ET
      $CERT
      Computer Software: Prepackaged Software
      Technology

    $CERT
    Financials

    Live finance-specific insights

    See more
    • Certara Reports First Quarter 2025 Financial Results

      RADNOR, Pa., May 05, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today reported its financial results for the first quarter of fiscal year 2025. First Quarter Highlights: Revenue was $106.0 million, compared to $96.7 million in the first quarter of 2024, representing growth of 10%. Software revenue was $46.4 million, compared to $39.3 million in the first quarter of 2024, representing growth of 18%.Services revenue was $59.6 million, flat compared to $57.3 million in the first quarter of 2024, representing growth of 4%. Net income was $4.7 million, a $9.4 million increase compared to a net loss of $4.7 million in t

      5/5/25 4:15:00 PM ET
      $CERT
      Computer Software: Prepackaged Software
      Technology
    • Certara Reports Preliminary First Quarter 2025 Financial Results; Announces $100 Million Share Repurchase Authorization

      Reiterates Full-Year 2025 GuidanceArsenal Capital Partners agrees to a one-year lock-up RADNOR, Pa., April 14, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today announced expected revenue and bookings for the first quarter of 2025 based upon a preliminary review of first quarter results. Additionally, the company announced that its Board of Directors has authorized a stock repurchase program under which the company may repurchase up to $100 million of its outstanding common stock. "We are pleased with our first quarter performance, driven by strong commercial execution and demand for our software and services," said

      4/14/25 8:00:00 AM ET
      $CERT
      Computer Software: Prepackaged Software
      Technology
    • Certara Reports Fourth Quarter 2024 Financial Results

      RADNOR, Pa., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today reported its financial results for the fourth quarter and full year 2024. Fourth Quarter Highlights: Revenue was $100.4 million, compared to $88.0 million in the fourth quarter of 2023, representing growth of 14%. Software revenue was $42.3 million, compared to $33.6 million in the fourth quarter of 2023, representing growth of 26%.Services revenue was $58.1 million, compared to $54.4 million in the fourth quarter of 2023, representing growth of 7%. Net income was $6.6 million, compared to a net loss of $12.5 million in the fourth quarter of 2023.Adjuste

      2/26/25 4:15:00 PM ET
      $CERT
      Computer Software: Prepackaged Software
      Technology